PHILADELPHIA, June 16, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) announced that a corporate update on operations has been provided on June 12, 2009 and can be accessed at BioMedReports.com. The interview provides current information on both regulatory and clinical fronts on the company’s platform technology, including Ampligen(r), an experimental therapeutic, and Alferon-N, a FDA approved product for treatment of refractory HPV, now being pursued as a potential treatment for pandemic influenza. To access the full interview, go to: http://biomedreports.com/articles/most-popular/1314-exclusive-interview-dr-william-a-carter-ceo-hemispherx-biopharma-inc-amexheb.html
